Medlab owns and runs an Office of the Gene Technology Regulator (OGTR) approved PC2 Biologic facility in NSW, Australia.
This is the primary site for research projects.
Presently we are involved in early phase drug discovery in 5 key areas:
Medlab has multiple patents pending on our products:
A new composition for the treatment of phrophylaxis of pain with secondary effects for the treatment of nausea and bulimia.
A new composition for the prophylactic treatment of kidney disease and/or improving kidney function.
A new composition for the treatment or prevention of mild to moderate depression, anxiety or a depressive or anxiety disorder.
A new composition for the treatment or prevention of muscle degeneration associated with age-related or injury-related muscle weakness or atrophy.
A new composition for the treatment of metabolic syndrome and obesity.
A new composition for heightening the innate immune system.
A new composition for stimulating mitochondrial function.
A new composition for the delivery and uptake of vitamin C in humans.
A new composition for nutritional and therapeutic compositions and methods.
Probiotic compositions and uses thereof for treatment of obesity-related disorders.
A probiotic and enzyme containing compositions and uses thereof.
Oral and/or nasal transmuscosal delivery systems.
Probiotic compositions for rehydration.
Yeast-containing compositions for gastrointestinal health.